Zobrazeno 1 - 10
of 30
pro vyhledávání: '"yanntong chiang"'
Autor:
Klaus K. Witte, Rolf Wachter, Michele Senni, Jan Belohlavek, Ewa Straburzynska‐Migaj, Candida Fonseca, Eva Lonn, Adele Noè, Heike Schwende, Dmytro Butylin, YannTong Chiang, Domingo Pascual‐Figal, the TRANSITION investigators
Publikováno v:
ESC Heart Failure, Vol 10, Iss 1, Pp 80-89 (2023)
Abstract Aims Diabetes mellitus is associated with worse outcomes and lower attainment of disease‐modifying therapies in patients with heart failure with reduced ejection fraction (HFrEF). This post hoc analysis of TRANSITION compared the patterns
Externí odkaz:
https://doaj.org/article/df824630d2f74d9c941a281fdcfaab06
Autor:
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco, Frederick J Raal
Publikováno v:
American Journal of Preventive Cardiology, Vol 13, Iss , Pp 100403- (2023)
Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agen
Externí odkaz:
https://doaj.org/article/0011f94e522840b59e2bf9b7e51e40ab
Autor:
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R S Wright, yanntong chiang, Lorena Garcia Conde Orozco, Frederick J Raal
Publikováno v:
Circulation. 144
Introduction: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent with twice-yearly subcutaneous dosing
Autor:
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Frederick J Raal, Kausik K Ray, Gregory G Schwartz, yanntong chiang, Lorena Garcia Conde Orozco, R S Wright
Publikováno v:
Circulation. 144
Introduction: Disorders of glucose metabolism increase in prevalence globally and contribute to excess risk of ASCVD, necessitating intensive lipid lowering. Aim: To analyze efficacy and safety of inclisiran (small interfering RNA targeting hepatic P
Autor:
YannTong Chiang, Rejane de Paula-Bernardes, Anna Wasilewska, Augustina Jankauskiene, Monique Tan, Robert Glazer, Kiran B. Bapatla, Michele A. Valentin, Dorota Drozdz
Publikováno v:
Current medical research and opinion. 37(12)
To assess the dose-response relationship for reduction in mean systolic blood pressure (MSBP) with valsartan solution, in young children with hypertension with or without chronic kidney disease (CKD).In this multicenter, randomized, double-blind, dou
Autor:
Ulf Landmesser, David G. Kallend, Wolfgang Koenig, Lawrence A. Leiter, Frederick J. Raal, Kausik Kumar Ray, Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco
Publikováno v:
Journal of the American College of Cardiology. 79:1555
Autor:
Ulrik M. Mogensen, Lars Køber, Claudio Gimpelewicz, Yanntong Chiang, Pardeep S. Jhund, Kenneth Dickstein, John J.V. McMurray, Mohammed Atif Ali, Søren Lund Kristensen, Georgia Tarnesby, William T. Abraham, Qing Shao
Publikováno v:
European Journal of Heart Failure. 20:136-147
Aims Because of concerns about the safety of aliskiren in patients with diabetes, study treatment was stopped prematurely in the Aliskiren Trial of Minimizing OutcomeS for Patients with HEart failuRE (ATMOSPHERE). We examined outcomes and treatment e
Autor:
YannTong Chiang, Kiran B. Bapatla, Robert Glazer, R De Paula Bernardes, Augustina Jankauskiene, Anna Wasilewska, Dorota Drozdz
Publikováno v:
European Heart Journal. 40
Background Hypertension is a leading cause of disability and mortality worldwide. In the paediatric population, hypertension and chronic kidney disease (CKD) have raised significant health concern due to the risk of target organ damage similar to tha
Autor:
null David R. Matthews, null Päivi M. Paldánius, null Michael Stumvoll, null Jackie Han, null Giovanni Bader, null YannTong Chiang, null Pieter Proot, null Stefano Del Prato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::effa76a49e5273aa81d9eab526c33493
https://doi.org/10.1111/dom.13800/v3/response1
https://doi.org/10.1111/dom.13800/v3/response1
Autor:
Pieter Proot, Jackie Han, YannTong Chiang, Michael Stumvoll, David R. Matthews, Giovanni Bader, Päivi M. Paldánius, Stefano Del Prato
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To ensure the integrity of the planned analyses and maximize the clinical utility of the VERIFY study results by describing the detailed concepts behind its statistical analysis plan (SAP) before completion of data collection and study database
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7f56d5880607e446c1e50a4fcae384
http://hdl.handle.net/11568/992672
http://hdl.handle.net/11568/992672